Epilepsy Epidemiology Forecast

DelveInsight’s ‘Epilepsy - Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Epilepsy epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Epilepsy Understanding

According to the American Association of Neurological Surgeons, epilepsy is a disorder of the brain characterized by repeated seizures. A seizure is usually defined as a sudden alteration of behavior due to a temporary change in the electrical functioning of the brain. Normally, the brain continuously generates tiny electrical impulses in an orderly pattern. These impulses travel along neurons – the network of nerve cells in the brain – and throughout the whole body via chemical messengers called neurotransmitters. In epilepsy, the brain’s electrical rhythms tend to become imbalanced, resulting in recurrent seizures. Moreover, in patients with seizures, the normal electrical pattern is disrupted by sudden and synchronized bursts of electrical energy that may briefly affect their consciousness, movements, or sensations.


Epilepsies have many possible causes, and there are several types of seizures. Anything that disturbs the normal pattern of neuron activity – from illness to brain damage to abnormal brain development – can lead to seizures.


Epilepsy may develop because of an abnormality in brain wiring, an imbalance of nerve signaling chemicals called neurotransmitters, changes in important features of brain cells called channels, or some combination of these and other factors.


If seizures ascend from a specific area of the brain, then the initial symptoms of the seizure often reflect the functions of that area. The right half of the brain controls the left side of the body, and the left half of the brain controls the right side of the body. For example, if a seizure starts from the right side of the brain in the area that controls movement in the thumb, then the seizure may begin with jerking of the left thumb or hand.

Epilepsy Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Epilepsy, Total Diagnosed Prevalent Population of Epilepsy, Gender-specific Diagnosed Prevalence of Epilepsy, Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults and Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Epilepsy Detailed Epidemiology Segmentation

  • The total prevalent population of Epilepsy in the seven major markets was found to be 7,190,297 in 2017. However, the total diagnosed prevalent population in the 7MM was 5,216,490 in 2017.
  • The diagnosed prevalent cases of Epilepsy, in the United States, were found to be 2,808,599 in 2017.
  • It was found that in the United States, the number of diagnosed prevalent cases of Generalized, Focal and Other determined and undetermined type of Epileptic seizures in adults was 770,288, 1,482,440 and 169,560, in 2017. 
  • On the other hand, the diagnosed prevalent cases of Generalized, Focal and Other determined and undetermined type of Epileptic seizures in children was 158,387, 212,471 and 15,452, in 2017, in the United States.
  • It was also found that in the United States, the number of males and females with Epilepsy was 1,477,323 and 1,331,276, respectively, in 2017.
  • In the EU5 countries, the prevalence of Epilepsy was found to be maximum in Germany with 645,784 cases, followed by the United Kingdom with 641,720 cases in 2017. While, the least number of cases were found in Spain, with 403,591 cases in 2017.
  • In Japan, the total prevalence of Epilepsy was estimated to be 1,012,659 in 2017.

Scope of the Report

  • The report covers the descriptive overview of Epilepsy, explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Epilepsy.
  • The report provides the segmentation of the disease epidemiology for the 7MM by Total Prevalent Population of Epilepsy, Total Diagnosed Prevalent Population of Epilepsy, Gender-specific Diagnosed Prevalence of Epilepsy, Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults and Diagnosed Prevalence of Epilepsy Based on Seizure types in Children.

Report Highlights

  • Eleven Year Forecast of Epilepsy
  • 7MM Coverage
  • Total Diagnosed Prevalent Population of Epilepsy
  • As per DelveInsight’s analysis, Epilepsy can be of three kinds on the basis of seizure-type, namely, Generalized, Focal and Other determined and undetermined seizures. The diagnosed prevalent numbers of these types differ in Children and Adults.
  • Delveinsight has also analysed gender-specific data regarding Epilepsy, which suggests that it is more prevalent in males than in females.

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Epilepsy?
  • What is the historical Epilepsy patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Epilepsy at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Epilepsy?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Epilepsy during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy

The Epilepsy report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Epilepsy market.
  • Quantify patient share distribution in the 7MM for Epilepsy.
  • The Epilepsy epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Epilepsy epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

1 Key Insights

2 Epilepsy Overview at a Glance

3 Executive Summary

4 Disease Background and Overview

4.1 Introduction

4.2 Seizure Types

4.2.1 Generalized Seizures

4.2.2 Focal Seizure

4.2.3 Unknown Seizures

4.3 Clinical Manifestations

4.4 Causes

4.5 Classification

4.5.1 Generalized onset seizures

4.5.2 Focal onset seizures

4.5.3 Unknown onset seizures

4.6 Types of Epilepsies

4.6.1 West Syndrome

4.6.2 Dravet syndrome

4.6.3 Lennox–Gastaut syndrome

4.6.4 Landau–Kleffner syndrome

4.6.5 Epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS)

4.6.6 CDKL5 deficiency disorder (CDD)

4.7 Risk Factors

4.8 Pathophysiology

4.9 Diagnosis

4.9.1 Imaging and Monitoring

4.9.2 Medical History

4.9.3 Blood Tests

4.9.4 Developmental, Neurological, and Behavioral Tests

4.10 Tuberous Sclerosis Complex (TSC) Mutations in Epilepsy

5 Epidemiology and Patient Population

5.1 Key Findings

5.2 7MM Total Prevalent Population of Epilepsy

5.3 7MM Diagnosed Total Prevalent Population of Epilepsy

6 Country-wise Epidemiology of Epilepsy

6.1 United States

6.1.1 Assumptions and Rationale

6.1.2 Total Prevalent Population of Epilepsy in the United States

6.1.3 Total Diagnosed Prevalent Population of Epilepsy in the United States

6.1.4 Gender-specific Diagnosed Prevalence of Epilepsy in the United States

6.1.5 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in the United States

6.1.6 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in the United States

6.2 EU5 Countries

6.2.1 Assumptions and Rationale

6.3 Germany

6.3.1 Assumptions and Rationale

6.3.2 Total Prevalent Population of Epilepsy in Germany

6.3.3 Total Diagnosed Prevalent Population of Epilepsy in Germany

6.3.4 Gender-specific Diagnosed Prevalence of Epilepsy in Germany

6.3.5 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Germany

6.3.6 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Germany

6.4 France

6.4.1 Assumptions and Rationale

6.4.2 Total Prevalent Population of Epilepsy in France

6.4.3 Total Diagnosed Prevalent Population of Epilepsy in France

6.4.4 Gender-specific Diagnosed Prevalence of Epilepsy in France

6.4.5 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in France

6.4.6 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in France

6.5 Italy

6.5.1 Assumptions and Rationale

6.5.2 Total Prevalent Population of Epilepsy in Italy

6.5.3 Total Diagnosed Prevalent Population of Epilepsy in Italy

6.5.4 Gender-specific Diagnosed Prevalence of Epilepsy in Italy

6.5.5 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Italy

6.5.6 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Italy

6.6 Spain

6.6.1 Assumptions and Rationale

6.6.2 Total Prevalent Population of Epilepsy in Spain

6.6.3 Total Diagnosed Prevalent Population of Epilepsy in Spain

6.6.4 Gender-specific Diagnosed Prevalence of Epilepsy in Spain

6.6.5 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Spain

6.6.6 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Spain

6.7 United Kingdom

6.7.1 Assumptions and Rationale

6.7.2 Total Prevalent Population of Epilepsy in the United Kingdom

6.7.3 Total Diagnosed Prevalent Population of Epilepsy in the United Kingdom

6.7.4 Gender-specific Diagnosed Prevalence of Epilepsy in the United Kingdom

6.7.5 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in the United Kingdom

6.7.6 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in the United Kingdom

6.8 Japan

6.8.1 Assumptions and Rationale

6.8.2 Total Prevalent Population of Epilepsy in Japan

6.8.3 Total Diagnosed Prevalent Population of Epilepsy in Japan

6.8.4 Gender-specific Diagnosed Prevalence of Epilepsy in Japan

6.8.5 Diagnosed Prevalence of Epilepsy on Seizure types in Adults in Japan

6.8.6 Diagnosed Prevalence of Epilepsy on Seizure types in Children in Japan

7 Appendix

7.1 Bibliography

7.2 Report Methodology

8 DelveInsight Capabilities

9 Disclaimer

10 About DelveInsight

List of Tables

Table 1 Summary of Epilepsy, Market, Epidemiology and Key Events (2017–2030)

Table 2 Total Prevalent Population of Epilepsy in the 7MM (2017–2030)

Table 3 Total Diagnosed Prevalent Population of Epilepsy in the 7MM (2017–2030)

Table 4 Total Prevalent Population of Epilepsy in the US (2017–2030)

Table 5 Total Diagnosed Prevalent Population of Epilepsy in the US (2017–2030)

Table 6 Gender-specific Diagnosed Prevalence of Epilepsy in the US (2017–2030)

Table 7 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in the US (2017–2030)

Table 8 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in the US (2017–2030)

Table 9 Total Prevalent Population of Epilepsy in Germany (2017–2030)

Table 10 Total Diagnosed Prevalent Population of Epilepsy in Germany (2017–2030)

Table 11 Gender-specific Diagnosed Prevalence of Epilepsy in Germany (2017–2030)

Table 12 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Germany (2017–2030)

Table 13 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Germany (2017–2030)

Table 14 Total Prevalent Population of Epilepsy in France (2017–2030)

Table 15 Total Prevalent Diagnosed Population of Epilepsy in France (2017–2030)

Table 16 Gender-specific Diagnosed Prevalence of Epilepsy in France (2017–2030)

Table 17 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in France (2017–2030)

Table 18 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in France (2017–2030)

Table 19 Total Prevalent Population of Epilepsy in Italy (2017–2030)

Table 20 Total Diagnosed Prevalent Population of Epilepsy in Italy (2017–2030)

Table 21 Gender-specific Diagnosed Prevalence of Epilepsy in Italy (2017–2030)

Table 22 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Italy (2017–2030)

Table 23 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Italy (2017–2030)

Table 24 Total Prevalent Population of Epilepsy in Spain (2017–2030)

Table 25 Total Diagnosed Prevalent Population of Epilepsy in Spain (2017–2030)

Table 26 Gender-specific Diagnosed Prevalence of Epilepsy in Spain (2017–2030)

Table 27 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Spain (2017–2030)

Table 28 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Spain (2017–2030)

Table 29 Total Prevalent Population of Epilepsy in the UK (2017–2030)

Table 30 Total Diagnosed Prevalent Population of Epilepsy in the UK (2017–2030)

Table 31 Gender-specific Diagnosed Prevalence of Epilepsy in the UK (2017–2030)

Table 32 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in the UK (2017–2030)

Table 33 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in the UK (2017–2030)

Table 34 Total Prevalent Population of Epilepsy in Japan (2017–2030)

Table 35 Total Diagnosed Prevalent Population of Epilepsy in Japan (2017–2030)

Table 36 Gender-specific Diagnosed Prevalence of Epilepsy in Japan (2017–2030)

Table 37 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adult in Japan (2017–2030)

Table 38 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Japan (2017–2030)

List of Figures

Figure 1 ILAE 2017 Classification of Seizure Types Basic Version

Figure 2 ILAE 2017 Classification of Seizure Types Extended Version

Figure 3 Classification of Seizure

Figure 4 Pathophysiology of Epilepsy

Figure 5 Total Prevalent Population of Epilepsy in the 7MM (2017–2030)

Figure 6 Total Diagnosed Prevalent Population of Epilepsy in the 7MM (2017–2030)

Figure 7 Total Prevalent Population of Epilepsy in the US (2017–2030)

Figure 8 Total Diagnosed Prevalent Population of Epilepsy in the US (2017–2030)

Figure 9 Gender-specific Diagnosed Prevalence of Epilepsy in the US (2017–2030)

Figure 10 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in the US (2017–2030)

Figure 11 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in the US (2017–2030)

Figure 12 Total Prevalent Population of Epilepsy in Germany (2017–2030)

Figure 13 Total Diagnosed Prevalent Population of Epilepsy in Germany (2017–2030)

Figure 14 Gender-specific Diagnosed Prevalence of Epilepsy in Germany (2017–2030)

Figure 15 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Germany (2017–2030)

Figure 16 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Germany (2017–2030)

Figure 17 Total Prevalent Population of Epilepsy in France (2017–2030)

Figure 18 Total Prevalent Diagnosed Population of Epilepsy in France (2017–2030)

Figure 19 Gender-specific Diagnosed Prevalence of Epilepsy in France (2017–2030)

Figure 20 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in France (2017–2030)

Figure 21 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in France (2017–2030)

Figure 22 Total Prevalent Population of Epilepsy in Italy (2017–2030)

Figure 23 Total Diagnosed Prevalent Population of Epilepsy in Italy (2017–2030)

Figure 24 Gender-specific Diagnosed Prevalence of Epilepsy in Italy (2017–2030)

Figure 25 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Italy (2017–2030)

Figure 26 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Italy (2017–2030)

Figure 27 Total Prevalent Population of Epilepsy in Spain (2017–2030)

Figure 28 Total Diagnosed Prevalent Population of Epilepsy in Spain (2017–2030)

Figure 29 Gender-specific Diagnosed Prevalence of Epilepsy in Spain (2017–2030)

Figure 30 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Spain (2017–2030)

Figure 31 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Spain (2017–2030)

Figure 32 Total Prevalent Population of Epilepsy in the UK (2017–2030)

Figure 33 Total Diagnosed Prevalent Population of Epilepsy in the UK (2017–2030)

Figure 34 Gender-specific Diagnosed Prevalence of Epilepsy in the UK (2017–2030)

Figure 35 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in the UK (2017–2030)

Figure 36 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in the UK (2017–2030)

Figure 37 Total Prevalent Population of Epilepsy in Japan (2017–2030)

Figure 38 Total Diagnosed Prevalent Population of Epilepsy in Japan (2017–2030)

Figure 39 Gender-specific Diagnosed Prevalence of Epilepsy in Japan (2017–2030)

Figure 40 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Japan (2017–2030)

Figure 41 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Japan (2017–2030)

  • Tags:
  • Epilepsy Epidemiology
  • Epilepsy
  • Epilepsy Pipeline
  • Epilepsy Companies
  • Epilepsy prevalent population
  • Epilepsy incident population
  • Epilepsy patients diagnosed
  • Epilepsy treatment algorithm

Forward to Friend

Need A Quote